Memorial Sloan-Kettering Cancer Center | MSK Department of Medicine, Gastrointestinal Research

Research site

(Unclaimed)

Location

300 East 66th Street, New York, New York, United States of America

Site insights

Top conditions

Top treatments

Lenalidomide

Gemcitabine

Pralatrexate

Sorafenib

Cytarabine

Docetaxel

Oxaliplatin

Doxorubicin

Taxane

CTO

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 60 total trials

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refracto...

Enrolling

MDS

AML, Adult Recurrent

Drug: Decitabine

Drug: LYT-200

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluat...

Active, not recruiting

Non-small Cell Lung Cancer

Castration-resistant Prostate Cancer

Drug: SM08502

Drug: Prednisone

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting

Urothelial Cancer

Drug: Erdafitinib

Drug: Docetaxel

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's...

Enrolling

Neoplasms, Ovarian

Drug: Topotecan

Drug: Paclitaxel

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling

Locally Advanced Solid Tumors

Primary CNS Tumors

Drug: Oral repotrectinib (TPX-0005)

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Cancer

Drug: nab-paclitaxel

Drug: gemcitabine

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Iberdomide

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patie...

Active, not recruiting

Hand-Foot Skin Reaction (HFSR)

Drug: OQL011

Drug: Vehicle Ointment

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous trea...

Enrolling

Lung Neoplasms

Bladder Cancer

Drug: brigimadlin

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole...

Active, not recruiting

Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

Drug: CTO and Temodar®

Drug: CTO

Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION)

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatmen...

Active, not recruiting

Tenosynovial Giant Cell Tumor, Diffuse

Giant Cell Tumor of Tendon Sheath

Drug: Placebo

Drug: vimseltinib